Search results
Results from the WOW.Com Content Network
Radiotherapy can induce a dose-dependent increase of furin-mediated cleavage of the ADAM17 proform to active ADAM17, which results in enhanced ADAM17 activity in vitro and in vivo. It was also shown that radiotherapy activates ADAM17 in non-small cell lung cancer, which results in shedding of multiple survival factors, growth factor pathway ...
Approximately 98% of lung cancers are carcinoma, a term describing malignancies derived from transformed cells exhibiting characteristics of epithelium. About 2% of all lung cancers are non-carcinoma (mainly sarcoma, tumors of hematopoietic origin, or germ cell tumors. [5] These forms of lung cancer are usually treated differently from carcinomas.
There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, melanoma and other cancers. [ 1 ] [ 4 ] [ 5 ] Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy.
The ADAM11 gene represents a candidate tumor suppressor gene for human breast cancer based on its location within a minimal region of chromosome 17q21 previously defined by tumor deletion mapping. [13] ADAM12: ADAM12, a metalloprotease that binds insulin growth factor binding protein-3 (IGFBP-3), appears to be an effective early Down syndrome ...
ADAM 17 endopeptidase (EC 3.4.24.86, tumor necrosis factor alpha-converting enzyme, TACE) is an enzyme. [1] This enzyme catalyses the following chemical reaction. Narrow endopeptidase specificity.
TAPI-1 (TNF-alpha protease inhibitor I) is a structural analog of TAPI-0 with similar but more stable validness [clarification needed] in vitro for the matrix metalloproteinases (MMPs) and TNF- alpha converting enzyme [1] which blocks shedding of several cell surface proteins such as IL-6 and p60 TNF receptor.
Crizotinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) or relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. [ 2 ] [ 3 ] It is also indicated for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive ...
Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [ 16 ] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [ 17 ]